Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (262) Arrow Down
Filter Results: (262) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (262)
    • News  (29)
    • Research  (197)
    • Multimedia  (2)
  • Faculty Publications  (103)

Show Results For

  • All HBS Web  (262)
    • News  (29)
    • Research  (197)
    • Multimedia  (2)
  • Faculty Publications  (103)
← Page 6 of 262 Results →
  • Research Summary

Overview

My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
Keywords: Mergers and Acquisitions; Corporate Governance; Valuation; Law
  • Research Summary

Overview

My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
Keywords: Mergers and Acquisitions; Corporate Governance; Valuation; Law
  • 08 Aug 2011
  • Research & Ideas

The Death of the Global Manager

while confirming and further exploring some basic challenges that have, more or less, remained the same. "There are three core strategies that any MNC has to pursue to build layers of competitive advantage," Bartlett says.... View Details
Keywords: by Julia Hanna
  • Web

Research - Global

was privatized in 2003, regional players started entering the Saudi market. To deal with the competition and to... May 2025 Teaching Material Eat App: Building and Monetizing an End-to-End Dining Experience Solution By: Elie Ofek and... View Details
  • 11 Apr 2024
  • In Practice

Why Progress on Immigration Might Soften Labor Pains

US firms to find workers more easily at times of high labor demand, while shielding US-born workers from labor market competition during recessions. Not all firms will benefit from a scenario in which high-skilled immigrants replace... View Details
Keywords: by Rachel Layne
  • October 2024
  • Case

Parexel: Scaling Up and Industry Dynamics

By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
Keywords: Research; Innovation and Invention; Business Model; Transformation; Globalization; Information Technology; Competitive Advantage; Pharmaceutical Industry
Citation
Educators
Related
Herzlinger, Regina E., and Ben Creo. "Parexel: Scaling Up and Industry Dynamics." Harvard Business School Case 325-046, October 2024.
  • Web

HBS - The year in Review

Prize: Gresnol Most Promising Deep Tech Venture $5,000 Prize: Phenegra Most Promising Pharmaceutical Venture $5,000 Prize: Believer Pharmaceuticals Alumni Track $75,000 Grand Prize: M7 Health $25,000... View Details
  • October 2010 (Revised November 2010)
  • Background Note

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details
Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
  • 26 Sep 2006
  • First Look

First Look: September 26, 2006

the improved ability of firms to replicate business innovations has affected not only productivity, but also the nature of business competition itself. Download working paper: http://www.hbs.edu/research/pdf/07-016.pdf   Cases &... View Details
Keywords: Sean Silverthorne
  • Web

2023 Reunion Presentations - Alumni

look like? Fueled by advances in digital technology, will a select few superstars in media and sports come to have a bigger impact on popular culture than they do now, and how will they use their power? Will we see bigger bets on likely blockbusters, more intense View Details

    William A. Sahlman

    William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School.

    Mr. Sahlman received an A.B. degree in Economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in Business... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

      Willis M. Emmons

      WILLIAM (WILLIS) EMMONS is Senior Lecturer and Director of the C. Roland Christensen Center for Teaching and Learning at Harvard Business School, a position he has held since 2004.  As Director of the Christensen Center, Emmons oversees programs to... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 23 Mar 2010
      • First Look

      First Look: March 23

      catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
      Keywords: Martha Lagace
      • 15 Jul 2013
      • Research & Ideas

      Five Imperatives for Improving Health Care

      pharmaceuticals, electronic medical records, and basic research. "We can't just wait for decentralized approaches to come and save us," Huckman says. "At some point we need to go to the large medical centers, group practices, and View Details
      Keywords: by Carmen Nobel; Health
      • Web

      Academics - Health Care

      how strategic principles can be applied in health care settings to identify sources of competitive advantage (and all too often, disadvantage). Our emphasis will be on payers and providers, but we will also devote 20-25% of our case... View Details
      • Web

      Health Care - Faculty & Research

      transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003 and chief... View Details
      • September 2012 (Revised November 2014)
      • Case

      Cialis Lifecycle Management: Lilly's BPH Dilemma

      By: Elie Ofek and Natalie Kindred
      How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details
      Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Ofek, Elie, and Natalie Kindred. "Cialis Lifecycle Management: Lilly's BPH Dilemma." Harvard Business School Case 513-005, September 2012. (Revised November 2014.)
      • 01 Jun 2024
      • News

      Quantum Leap

      “This is the first new kind of computer in 75 years,” says John Levy (MBA 1979), CEO of the quantum computing startup SEEQC. “And we’re building it on a chip!” Strolling through his company’s design and testing facility in Elmsford, New York, Levy looks less like a... View Details
      Keywords: Alexander Gelfand; photographed by Chris Sorensen; quantum computing; innovation; leadership; Computer and Electronic Product Manufacturing; Manufacturing

        John A. Deighton

        John Deighton is The Harold M. Brierley Professor of Business Administration Emeritus at Harvard Business School. He is an authority on consumer behavior and marketing, with a focus on digital and direct marketing. He teaches in the area of Big Data in Marketing,... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • February 2024
        • Case

        Compass Pathways: Pioneering Psychedelic Treatment

        By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
        This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
        Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
        Citation
        Educators
        Purchase
        Related
        Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
        • ←
        • 6
        • 7
        • …
        • 13
        • 14
        • →
        ǁ
        Campus Map
        Harvard Business School
        Soldiers Field
        Boston, MA 02163
        →Map & Directions
        →More Contact Information
        • Make a Gift
        • Site Map
        • Jobs
        • Harvard University
        • Trademarks
        • Policies
        • Accessibility
        • Digital Accessibility
        Copyright © President & Fellows of Harvard College.